

This is the peer reviewed version of the following article:

Are climacteric complaints associated with risk factors of cardiovascular disease in peri-menopausal women? / Cagnacci, Angelo; Palma, Federica; Romani, Cecilia; Xholli, Anjeza; Bellafronte, Manuela; Di Carlo, Costantino. - In: GYNECOLOGICAL ENDOCRINOLOGY. - ISSN 0951-3590. - STAMPA. - 31:5(2015), pp. 359-362. [10.3109/09513590.2014.998188]

Terms of use:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

21/07/2024 00:07

(Article begins on next page)



Are climacteric complaints associated with risk factors of cardiovascular disease in perimenopausal women?

| | |
|-------------------------------|--|
| Journal: | <i>Gynecological Endocrinology</i> |
| Manuscript ID: | DGYE-2014-0360.R1 |
| Manuscript Type: | Original Paper |
| Date Submitted by the Author: | n/a |
| Complete List of Authors: | Cagnacci, Angelo; Azienda Policlinico di Modena, Palma, Federica; Azienda Policlinico di Modena, Romani, Cecilia; Azienda Policlinico di Modena, Xholli, Anjeza; Azienda Policlinico di Modena, bellafronte, manuela; Azienda Policlinico di Modena, Di Carlo, Costantino; Università Federico II di Napoli, |
| Keywords: | Menopause, Cardiovascular risk, Lipid, Mood, Hot Flush |
| | |

SCHOLARONE™
Manuscripts

Only

1
2
3 1 **Are climacteric complaints associated with risk factors of cardiovascular disease**
4
5 2
6 **in perimenopausal women?**

7 3 Angelo Cagnacci MD, PhD¹, Federica Palma MD¹, Cecilia Romani MD¹, Anjeza Xholli MD¹,
8 4 Manuela Bellafronte MD¹, Costantino Di Carlo MD².

9
10
11 5
12
13 6 ¹Department Obstetrics Gynecology and Pediatrics, Obstetrics and Gynecology Unit,
14 7 Azienda Ospedaliero-Universitaria of Modena, Italy

15
16
17 8 ²Department of Neurosciences and Reproductive Sciences, University of Naples Federico
18 9 II, Naples , Italy.

19
20
21
22 10
23
24 11 **Correspondence to:** Angelo Cagnacci MD, PhD, Dipartimento Integrato Materno-Infantile,
25 12 Ginecologia e Ostetrica, Azienda Ospedaliero-Universitaria di Modena, via del Pozzo 71, 41100
26 13 Modena, Italy.

27
28
29
30 14 Tel 39 059 4222851; Fax 39 059 4224394; email cagnacci@unimore.it
31
32 15

33
34 16 **Running Title:** Symptoms and CVD risk

35
36 17 **Key Words:** Menopause, Lipid, Cardiovascular risk, Mood, Hot Flush
37
38 18

39
40 19 **Funding Source:** None
41
42 20
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 21 **Abstract**
4

5 22 Recent studies indicate that metabolic risk for cardiovascular disease is increased in postmenopausal
6
7 23 women suffering from disturbances such as hot flushes. In order to evaluate whether this is true also
8
9 24 in peri-menopausal women we performed an observational study on 590 peri-menopausal women of
10
11 25 an outpatient center at a University Hospital. Each cardiovascular risk factor such as blood pressure,
12
13 26 fasting glucose, fasting lipids and the ten year risk for cardiovascular disease was tested for its
14
15 27 relation to climacteric complaints. The Greene's climacteric scale, and its subscales were used to
16
17 28 evaluate climacteric symptoms. Analyses were corrected for confounders derived by personal history
18
19 29 and anthropometric measures. When corrected for confounders the Greene's score was a positive
20
21 30 determinant of triglycerides ($R^2=0.249$; $p=0.0001$), triglycerides/HDL-cholesterol ($R^2=0.316$;
22
23 31 $p=0.0001$), glucose ($R^2=0.101$; $p=0.0003$), and the 10-year risk for cardiovascular disease, calculated
24
25 32 by the Framingham formula ($R^2=0.081$; $p=0.0001$). The Greene's vasomotor sub-score was an
26
27 33 independent determinant of LDL-cholesterol ($R^2=0.025$; $p=0.01$), and LDL/HDL-cholesterol
28
29 34 ($R^2=0.143$; $p=0.0001$), while the Greene's depression sub-score was a negative determinant of HDL-
30
31 35 cholesterol ($R^2=0.179$; $p=0.0001$). The data indicate that also in peri-menopausal women, menopausal
32
33 36 symptoms evaluated by a validated climacteric scale are associated with biochemical risk factors for
34
35 37 atherosclerosis and cardiovascular disease.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1. Introduction

Recent studies indicate that postmenopausal women suffering from disturbances such as hot flushes may be at increased risk for cardiovascular disease. They have a higher BMI [1-3], higher blood pressure [4], increased aortic and artery calcification [5,6], reduced flow-mediated endothelium-dependent vasodilatation [5,6] and a less favorable lipid profile [7]. At the moment it is unclear whether these relations do occur also in women in the peri-menopausal period. This is a period in which clinical disturbances and metabolic changes start to occur, as the consequence of ovarian endocrine modification [8-10]. In one study selectively performed in peri-menopausal women higher vasomotor symptoms were reported to be associated with higher levels of both atherogenic (LDL and triglycerides) and anti-atherogenic (HDL-) lipoproteins [11]. Hot flushes are associated with sleep and mood disturbances [12,13] and these disturbances increase in peri-menopausal women [14,15]. Accordingly, analyses evaluating the bulk of climacteric disturbances are probably more appropriate in determining the impact that these may exert on women's health. Recently, we reported that in postmenopausal women the extent of menopausal disturbances as evaluated by the Greene climacteric scale, is related to endocrine and metabolic modifications possibly leading to an increased cardiovascular risk [16,17]. In this cross-sectional investigation we wanted to evaluate whether the same applies to women in the peri-menopausal period.

2. Methods

Data of women attending the outpatient service for the menopause at our University Hospital in Modena were retrospectively retrieved from an electronic database. Symptomatic but also asymptomatic women that are interested in health prevention attend the service. Once entering in our center, each woman signs a consent form for the anonymous use of her personal data in research. The Institutional Review Board approved the anonymous extraction of the data of interest. Of the 4322 consultations at the Center performed between May 2005 and December 2012, 525 were excluded because women were on hormonal therapy possibly interfering with items evaluated by the Greene climacteric scale (progestins, estrogens or estrogens plus progestins). Of the remaining 3797 consultations, 920 were performed in postmenopausal women, 98 in the reproductive stages below -3 (premenopause) of the STRAW classification (a well recognized although not wholly reliable method to assess different reproductive life stages) [18] and 79 had incomplete data. We used only the data of the entry visit and excluded the 2110 re-evaluations performed on the same subjects. Accordingly, analysis was performed on 590 peri-menopausal women, (reproductive stage -2 and -1 of the STRAW classification). In these women FSH levels were higher than 30 IU/L and each woman had a period of amenorrhea <12 months.

For each single woman we extracted data such as: age, age at menarche, history of hypertension (no/yes), diabetes (no/yes), smoking behavior (never, past, current), leisure activity (low, moderate, elevated), daily use of wine, beer (no/yes) or daily use of alcoholic beverages (no/yes), use of cholesterol-lowering medicine (no/yes), education level (primary, intermediate; higher; university), height (m), weight (kg), body mass index (BMI; Kg/m²), waist and hip girth, waist/hip ratio, systolic and diastolic blood pressure, fasting levels of glucose, LDL-cholesterol, HDL-cholesterol, triglycerides, LDL-cholesterol/HDL-cholesterol, and triglyceride/HDL-cholesterol. The Framingham risk score was calculated on the basis of risk factors for cardiovascular disease [19]. Weight (in kilograms) and height (in meters) reported in the records had been measured while women were wearing light clothes and no shoes. While in standing position, the girths of the women had been measured along the horizontal plane at the level of the natural waist (narrowest abdominal

1
2
3 85 circumference) and at the level of the hip (maximum extension of the buttocks). Office blood
4
5 86 pressure had been measured after at least 10 minutes in a sitting position.

7 87 Scores of validated Italian translation of self-administered questionnaires evaluating climacteric
8
9 88 symptoms, anxiety and depressive symptoms were retrieved.

11 89 The Greene's climacteric scale was used to evaluate climacteric symptoms [20]. The Greene's
12
13 90 climacteric scale is composed of 21 items that evaluate vasomotor symptoms (two items), anxiety (six
14
15 91 items), depression (five items), somatic symptoms (seven items), and sexuality (one item). For
16
17 92 vasomotor symptoms the two questions were "do you suffer from hot flushes?" and "do you suffer
18
19 93 from night sweat?". All items have four options that range from not at all (0), a little (1), quite a bit
20
21 94 (2), to extremely (3). The sum of items score is used to obtain the Greene climacteric scale score as a
22
23 95 whole (range 0-63) or the scores of individual sub-scales for vasomotor symptoms (range, 0 to 6),
24
25 96 anxiety (range, 0 to 18), depression (range, 0 to 15), somatic symptoms (range, 0 to 21) and sexuality
26
27 97 (range, 0 to 3). Total score and subscales scores were used into the analysis, as numerical data.

29 98 The Y-1 form of the State-Trait-Anxiety-Inventory (STAI) was used to further evaluate state of
30
31 99 anxiety [21] and the Zung Scale (SDS) to further evaluate depression [22]. These scales are made up
32
33 100 of 20 questions with 4 possible answers (score 1-4). Scores range from 20 (best) to 80 (worst).

35
36 101

38 102 2.1. Assays

40 103 Serum total cholesterol and triglycerides had been measured by enzymatic methods (Olympus
41
42 104 AU400, Olympus Diagnostic GmbH, Lismeehan, Ireland), while HDL-cholesterol had been
43
44 105 determined after precipitation with PEG 6000. The assay for cholesterol has a sensitivity of 5 mg/dL
45
46 106 and a coefficient of variation (CV) of 3%. LDL-cholesterol was calculated accordingly to the
47
48 107 Friedewald formula. Glucose had been determined by the glucose oxidase method. This assay has a
49
50 108 CV of 1.4%.

51
52 109

54 110 2.2. Statistical Analyses

56 111 Statistical analyses were performed by the statistical Package Statview 5.0.1 for Apple Macintosh
57
58 112 (SAS Institute Inc, Cary, NC, USA1998).

1
2
3 113 Each single biochemical cardiovascular risk factor such as HDL-cholesterol, LDL-cholesterol,
4
5 114 triglycerides, glucose, LDL-cholesterol/HDL-cholesterol ratio the triglyceride/HDL-cholesterol ratio
6
7 115 and the ten-year cardiovascular risk by Framingham risk score, as well as, systolic and diastolic blood
8
9 116 pressure, was tested by multivariate analysis for its relation to each scale score (SDS, STAI, Greene's
10
11 117 and its subscores) along with age, age at menarche, presence of hypertension and diabetes, use of
12
13 118 cholesterol-lowering medicine, leisure activity, smoking, level of education, BMI, waist/hip ratio. and
14
15 119 FSH values. FSH was used as an indirect index of hypo-estrogenism, more strongly related than any
16
17 120 other hormone to stages of menopausal transition and climacteric symptoms [16, 23]. Numerical data
18
19 121 were entered into the analyses, as continuous data. Categorical data such as history of hypertension,
20
21 122 of diabetes and use of cholesterol lowering medicine were entered into the analysis as single dummy
22
23 123 variable, smoking behavior and leisure activity, as two dummy variables, and education as 3 dummy
24
25 124 variables. For dummy variables the reference category was the absence of disease, medicine use,
26
27 125 smoking, leisure activity or low education. Adjusted regression coefficients of independent
28
29 126 determinants were obtained for each cardiovascular risk factor and the ten years cardiovascular risk.
30
31 127 For all analyses a p value <0.05 was considered as significant. All results are expressed as mean \pm
32
33 128 standard deviation (SD).
34
35
36 129
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3. Results

Enrolled women had a mean age of 49.6 ± 4.0 yr., BMI of 26.2 ± 4.8 and a waist/hip ratio of 0.85 ± 0.09 .

Ninety-one percent were married or in a long-term stable relationship, and 58.8% with a low grade of

education. Among them, 43.5% engaged in leisure activities, 3.6% suffered from diagnosed

hypertension and 0.5% suffered from diagnosed diabetes. Wine or beer were used daily by 43.5% of

the women, while spirits were used by 1.65% of them. The ten-year probability of cardiovascular

disease was 2.25 ± 5.3 . The score of the Greene Climacteric scale was 27.3 ± 13.3 , of the STAI scale

was 47.2 ± 10.0 , and of the SDS scale was 38.0 ± 9.9 (Table 1). Women that were excluded for missing

data did not differ from analyzed women in any of the parameters considered (data not shown).

Neither STAI nor SDS scores were related independently to any biochemical or biophysical risk

factor for cardiovascular disease. Data that were not independently related to any of the

cardiovascular risk factor taken into consideration are not presented.

Most cardiovascular risk factors were independently related to BMI and waist/hip ratio (Table 2). On

the other hand, multiple regression analysis revealed that also the Greene's Climacteric score and

sometimes some of its sub-scores were independently related to most biochemical indexes of

cardiovascular disease (Table 2).

When corrected for confounders, along with BMI and waist/hip ratio the Greene's score was a

positive determinant of triglycerides ($R^2=0.249$; $p=0.0001$), triglycerides/HDL-cholesterol ($R^2=0.316$;

$p=0.0001$), glucose ($R^2=0.101$; $p=0.0003$), and the 10-year risk for cardiovascular disease calculated

by the Framingham formula ($R^2=0.081$; $p=0.0001$). The Greene's vasomotor sub-score was the only

parameter independently related to LDL-cholesterol ($R^2=0.025$; $p=0.01$) and along with BMI and

waist/hip ratio it was an independent determinant of LDL/HDL-cholesterol ($R^2=0.143$; $p=0.0001$).

The Greene's depression sub-score was a negative determinant of HDL-cholesterol along with BMI

and waist/hip ratio ($R^2=0.179$; $p=0.0001$)(Table 2).

The Greene's score or its sub-scores were not determinants of blood pressure values. Positive

determinants of systolic blood pressure were ($R^2=0.090$; $p=0.0001$) age ($\beta = 0.717$; 95% confidence

interval (CI) 0.409; 1.025), BMI ($\beta = 0.598$; 95% CI 0.335; 0.861), and waist/hip ratio ($\beta = 17.1$; 95%

1
2
3 157 CI 2.5;31.8). Positive determinants of diastolic blood pressure were ($R^2=0.091$; $p=0.0001$) age ($\beta =$
4
5 158 0.377 ; 95%CI 0.169; 0.584) and BMI ($\beta =0.564$; 95% CI 0.387; 0.742).
6
7 159
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review Only

4. Discussion

The data herein obtained confirm that also in peri-menopausal women the extent of climacteric complaints is associated with an enhanced risk of cardiovascular disease. In women across the menopause hot flushes are directly related to unfavorable metabolic modifications or sub-clinical indexes of cardiovascular disease [1-7]. Hot flushes are related to mood complaints [14,15], and along with them they characterize the bulk of menopausal disturbances. The Greene's climacteric scale is a combination of sub-scales evaluating vasomotor complaints, mood, somatization, and sexuality. Accordingly, it summarizes the burden of climacteric disturbances. The present study was performed in a selected population of perimenopausal women, and it shows that the Greene's scores are related to biochemical cardiovascular risk factors, to the Framingham calculation of the ten years risk of cardiovascular disease and to the triglyceride/HDL-cholesterol ratio. The latter is not included in the Framingham calculation, but it is still considered an independent risk factor for cardiovascular disease [24,25]. Similar data, were obtained, although inconsistently [26], in women mostly in postmenopause [7,16,17], by the evaluation of hot flushes alone.

The association of climacteric symptoms with some cardiovascular risk factors may indicate a general vulnerability of selected women to gonadal steroid fluctuations of the perimenopause. On the other hand, it may also indicate a cause-effect relationship. It is difficult to hypothesize that climacteric symptoms are induced by metabolic abnormalities, but the opposite is possible. An increased catecholaminergic activity (27), and modification in calcitonin-related peptide [28] may represent mechanisms linking hot flushes with an increased cardiovascular risk. In postmenopausal women, we proposed that stressful menopausal symptoms increase cortisol production, and, as the consequence, insulin resistance and alterations of lipid metabolism [16,17]. Present data indicate that this may be true also in peri-menopausal women, where the Greene's scores were related to biochemical modifications clustering in the metabolic syndrome such as decreased HDL, increased triglycerides, and increased glucose.

Blood pressure was not related to the Greene's climacteric score. Data on the association between hot flushes and blood pressure are mixed with some reporting an association [4,7] and others not [29]. It

1
2
3 187 is possible that for the limited number of the considered subjects, our study failed to find a significant
4
5 188 association between climacteric symptoms and blood pressure values.
6

7 189 This study has several limitations. The study was hospital-based and its results could not be applied to
8
9 190 the general population. It has a cross-sectional design, which is, by the way, similar to many
10
11 191 previously published studies [3-7, 16,17]. The study is based on subjective answers to questions with
12
13 192 no objective evaluation. This is particularly true for the Greene's vasomotor scale that was based on
14
15 193 two questions testing patient's bother associated with symptoms rather than frequency or severity of
16
17 194 the symptoms. Nevertheless, the strength of this study is that it is not limited to hot flushes, a highly
18
19 195 specific but single index of climacteric complaints, but instead it presents a more exhaustive
20
21 196 evaluation of symptoms experienced by women across the menopausal transition. Furthermore, some
22
23 197 confounding, such as the use of any hormone therapy were excluded.
24

25 198 In conclusion, the present study supports the view that menopausal symptoms may be associated with
26
27 199 certain biochemical risk factors for cardiovascular disease. The data indicate that these modifications
28
29 200 start to occur very early, in the peri-menopause in association with the increase of menopausal
30
31 201 complaints. Although, the correlations between the Greene Climacteric scale and the various
32
33 202 outcomes account for only 10 to 30% of the variance, they indicate a metabolic change versus an un-
34
35 203 favorable condition that may possibly worsen with time. The data reinforce the view of proactively
36
37 204 treating climacteric complaints as soon as they present. Likely, an early treatment contributes to
38
39 205 prevent unfavorable metabolic modifications, but this possibility has yet to be fully explored.
40
41
42 206

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

207 **Declaration of Interest**

208 None of the Authors declared any conflict of interest with this study.

209

210

For Peer Review Only

211 5. References

- 212 [1] Den Tonkelaar I, Seidell JC, van Noord PA. Obesity and fat distribution in relation to hot
213 flashes in Dutch women from the DOM project. *Maturitas* 1996; 23:301-5.
- 214 [2] Freedman RR. Pathophysiology and treatment of menopausal hot flashes. *Semin*
215 *Reprod Med* 2005; 23:117-25.
- 216 [3] Thurston RC, Sowers MR, Sutton-Tyrrell K, Eversone-Rose SA, Lewis TT,
217 Edmundowicz D, Matthews KA. Abdominal adiposity and hot flashes among midlife
218 women. *Menopause* 2008;15:429-34.
- 219 [4] Gerber LM, Sievert LL, Warren BA, Pickering TG, Schwartz JE. Hot Flashes are
220 associated with increased ambulatory systolic blood pressure. *Menopause* 2007;14:308-
221 15.
- 222 [5] Thurston RC, Sutton-Tyrrell K, Everson-Rose SA, Hess R, Matthews KA. Hot
223 Flashes and subclinical cardiovascular disease: findings from the study of women's
224 health across the nation heart study. *Circulation* 2008; 118:1234-40.
- 225 [6] Bechlioulis A, Kalantaridou SN, Naka KK, Chatzikyriakidou A, Calis KA,
226 Makrigiannakis A, Papanikolau O, Kaponis A, Katsouras C, Georgiou I, Chrousos GP,
227 Michalis LK. Endothelial function, but not carotid intima-media thickness, is affected
228 early in menopause and is associated with severity of hot flushes. *J Clin Endocrinol*
229 *Metab* 2010; 95:1199-206.
- 230 [7] Gast GC, Grobbee DE, Pop VJ, Keyzer JJ, WiJnands-van Gent CJ, Samsioe GN,
231 Nilsson PM, van der Schouw YT. Menopausal complaints are associated with
232 cardiovascular risk factors. *Hypertension* 2008; 51:1492-8.
- 233 [8] Mishra GD, Kuh D. Health symptoms during midlife in relation to menopausal
234 transition:British prospective cohort study. *BMJ* 2012;344:e402. doi: 10.1136/bmj.e402

- 1
2
3 235 [9] Lovejoy JC, Champagne CM, de Jonge , Xie H, Smith SR. Increased visceral fat and
4
5 236 decreased energy expenditure during the menopausal transition. *Int J Obes (Lond)* 2008;
6
7 237 32: 949–58.
8
9
10 238 [10] Santoro N, Taylor SE. Reproductive Hormones and the Menopause Transition.
11
12 239 *Obstet Gynecol Clin North Am* 2011;38: 455–66.
13
14 240 [11] Thurston RC, El Khoudary SR, Sutton-Tyrrell K, Crandall CJ, Gold EB, Sternfeld
15
16 241 B, Joffe H, Selzer F, Matthews KA. Vasomotor symptoms and lipid profiles in women
17
18 242 transitioning through the menopause. *Obstet Gynecol* 2012; 119:753-61.
19
20 243 [12] Freeman EW, Sammel MD, Lin H. Temporal association of hot flashes and
21
22 244 depression in the transition to menopause. *Menopause* 2009; 16:728-34.
23
24 245 [13] Seritan AL, Iosif A-M, Park JH, DeatherageHand D, Sweet RL, Gold EB. Self-
25
26 246 reported anxiety, depressive, and vasomotor symptoms: a study of perimenopausal
27
28 247 women presenting to a specialized midlife assessment center. *Menopause* 2010; 17:410-
29
30 248 5.
31
32 249 [14] Kravitz HM, Ganz PA, Bromberger J, Powell LH, Sutton-Tyrrell K, Meyre PM.
33
34 250 Sleep difficulty in women at midlife: a community survey of sleep and the menopausal
35
36 251 transition. *Menopause* 2003; 10:19-28.
37
38 252 [15] Cagnacci A, Volpe A, Arangino S, Malmusi S, Draetta FP, Matteo ML, Volpe A.
39
40 253 Depression and anxiety in climacteric women: role of hormone replacement therapy.
41
42 254 *Menopause* 1997; 4:206-11.
43
44 255 [16] Cagnacci A, Cannoletta M, Caretto S, Zanin R, Xholli A, Volpe A. Increased
45
46 256 cortisol. A possible link between climacteric symptoms and cardiovascular risk factors.
47
48 257 *Menopause* 2011; 18:273-8.
49
50 258 [17] Cagnacci A Cannoletta M, Palma F, Zanin R, Xholli A, Volpe A. Menopausal
51
52 259 symptoms and risk factors for cardiovascular disease in postmenopause. *Climacteric*
53
54 260 2012; 15:157-62.
55
56
57
58
59
60

- 1
2
3 261 [18] Executive summary: Stages of Reproductive Aging Workshop (STRAW) Park City,
4
5 262 Utah, July, 2001. *Menopause* 2001; 8:402-7.
6
7 263 [19] Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel B. Prediction of
8
9 264 coronary heart disease using risk factor categories. *Circulation* 1998; 97:1837-47.
10
11 265 [20] Greene JG. Constructing a standard climacteric scale. *Maturitas* 1998; 29:25-31.
12
13 266 [21] Spielberg CD, Gorsuch RL, Lushene RE. Manual for the State-Trait Anxiety Inventory
14
15 267 (self-evaluation questionnaire). Palo Alto CA, Consulting Psychologists Press,1970.
16
17 268 [22] Zung WWK. A self-rating depression scale. *Arch Gen Psychol* 1965;12:63-70.
18
19 269 [23] Randolph JF Jr, Sowers M, Bondarenko I, Gold EB, Greendale GA, Bromberger JT,
20
21 270 Brockwell SE, Matthews KA. The relationship of longitudinal change in reproductive hormones
22
23 271 and vasomotor symptoms during the menopausal transition. *J Clin Endocrinol Metab* 2005;
24
25 272 90:6106-12.
26
27 273 [24] Frohlich J, Dobiasova M. Fractional esterification rate of cholesterol and ratio of
28
29 274 triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary
30
31 275 angiography. *Clin Chem* 2003; 49; 1873-80.
32
33 276 [25] Bittner V, Johnson D, Zineh I, Rogers WJ, Vido D, Marroquin OC, Bairey-Merz CN, Sopko
34
35 277 G. The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in
36
37 278 women with suspected myocardial ischemia:a report from the women's ischemia syndrome
38
39 279 evaluation (WISE). *Am Heart J* 2009;157:548-55.
40
41 280 [26] Tuomikoski P, Mikkola TS, Hamalainen E, Tikkanen MJ, Turpeinen U, Ylikorkala O.
42
43 281 Biochemical markers for cardiovascular disease in recently postmenopausal women with and
44
45 282 without hot flashes. *Menopause* 2010;17:315-20.
46
47 283 [27] Gupta P, Harte AL, da Silva N, Khan H, Barnett AH, Kumar S, Sturdee DW, McTernan PG.
48
49 284 Expression of calcitonin gene-related peptide, adrenomedullin, and receptor modifying proteins
50
51 285 in human adipose tissue and alteration in their expression with menopause status. *Menopause*
52
53 286 2007; 14: 1031-8.
54
55
56
57
58
59
60

- 1
2
3 287 [28] Gupta P, Harte AL, Sturdee DW, Sharma A, Barnett AH, Kumar S, McTernan PG. Effects
4
5 288 of menopausal status and circulating calcitonin gene-related peptide and adipokines: implications
6
7 289 for insulin resistance and cardiovascular risks. *Climacteric* 2008;18:364-72.
8
9 290 [29] Gallicchio L, Miller SR, Zacur H, Flaws JA. Hot flashes and blood pressure in midlife
10
11 291 women. *Maturitas* 2010; 65:69-74.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review Only

Table 1. Baseline characteristics (mean±SD) of the study population.

| | |
|--|------------|
| Age (yrs.) | 49.6±4.0 |
| BMI (kg/m ²) | 26.2±4.8 |
| Waist/Hip | 0.85±0.09 |
| Blood Pressure systolic (mmHg) | 128.4±19.8 |
| Blood Pressure diastolic (mmHg) | 77.1±12.8 |
| Waist/Hip | 0.85±0.09 |
| HDL-Cholesterol (mmol/l) | 1.66±0.41 |
| LDL-Cholesterol (mmol/l) | 3.89±1.36 |
| Triglycerides (mmol/l) | 1.10±0.59 |
| Glucose (mmol/l) | 5.09±0.82 |
| LDL-cholesterol/HDL-Cholesterol | 2.25±1.04 |
| Triglycerides/HDL-Cholesterol | 0.77±0.57 |
| Ten-Year probability of CVD* | 2.25±5.3 |
| State-trait anxiety score (range 20-80) | 47.2±10.0 |
| SDS score (range 20-80) | 38.0±9.9 |
| Greene's climacteric score (range 0-63) | 27.3±13.1 |
| Greene's anxiety sub-score (range 0-18) | 6.6±3.9 |
| Greene's depression sub-score (range 0-15) | 5.9±3.7 |
| Greene's somatic sub-score (range 0-21) | 5.6±4.0 |
| Greene's vasomotor sub-score (range 0-6) | 2.6±2.1 |
| Greene's sexuality sub-score (range 0-3) | 1.3±1.1 |

* calculated accordingly to the Framingham formula [20]. CVD=cardiovascular disease

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Adjusted regression coefficients by multiple regression analysis of independent determinants of each cardiovascular risk factor and of the ten-year risk for cardiovascular disease (CVD).

| Risk Factor | Determinant | β coefficient | 95% CI |
|----------------------------------|---------------------|---------------------|----------------|
| HDL-Cholesterol (mmol/l) | Greene depression | -0.029 | -0.056; -0.084 |
| | <i>BMI</i> | -0.025 | -0.038; -0.013 |
| | <i>Waist/Hip</i> | -0.787 | -1.52; -0.002 |
| LDL-Cholesterol (mmol/l) | Greene vasomotor | 0.012 | 0.001; 0.025 |
| LDL-Cholesterol/HDL- Cholesterol | Greene vasomotor | 0.063 | 0.002; 0.0168 |
| | <i>BMI</i> | 0.042 | 0.008; 0.077 |
| | <i>Waist/Hip</i> | 2.83 | 0.788; 4.89 |
| Triglycerides (mmol/l) | Greene total | 0.07 | 0.0004; 0.013 |
| | <i>BMI</i> | 0.039 | 0.0021; 0.058 |
| | <i>Waist/Hip</i> | 2.54 | 1.46; 3.61 |
| Triglycerides/HDL-Cholesterol | Greene total | 0.06 | 0.022; 0.095 |
| | <i>BMI</i> | 0.032 | 0.016; 0.049 |
| | <i>Waist/Hip</i> | 2.65 | 1.65; 3.64 |
| Glucose (mmol/l) | Greene total | 0.011 | 0.002; 0.020 |
| | <i>BMI</i> | 0.033 | 0.006; 0.061 |
| | <i>Waist/Hip</i> | 1.64 | 0.17; 3.12 |
| Ten-Year Risk for CVD | Greene total | 0.046 | 0.006; 0.087 |
| | <i>BMI</i> | 0.157 | 0.046; 0.267 |
| | <i>Waist/Hip</i> | 13.98 | 7.16; 20.8 |

Regression models are adjusted for age, age at menarche, presence of hypertension, diabetes, use of cholesterol lowering medicine, smoking, leisure activity, level of education and FSH values.

*The Ten-Year risk was calculated by the Framingham formula [19]. In this case the model was not adjusted for age and smoking, because these two parameters are necessary to calculate the ten-year risk.

1
2
3 I declare that I participated in the ideation, analysis and writing and that I have seen the final
4 version. I have no conflict of interest

5
6 Angelo Cagnacci
7

8
9
10 I declare that I participated in the ideation and clinical management of patients and that I
11 have seen the final version. I have no conflict of interest

12
13 Federica Palma
14

15
16 I declare that I participated in the ideation and clinical management of patients and that I
17 have seen the final version. I have no conflict of interest

18
19
20 Cecilia Romani
21

22
23 I declare that I participated in the ideation and statistical analysis and that I have seen the
24 final version. I have no conflict of interest

25
26 Anjeza Xholli
27

28
29
30 I declare that I participated in the ideation, clinical management and writing and that I have
31 seen the final version. I have no conflict of interest

32
33 Manuela Bellafronte
34

35
36
37 I declare that I participated in the ideation, statistical analysis and writing and that I have
38 seen the final version. I have no conflict of interest

39
40 Costantino di Carlo
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60